首页> 外文期刊>Metabolism: Clinical and Experimental >Portal vein and systemic adiponectin concentrations are closely linked with hepatic glucose and lipoprotein kinetics in extremely obese subjects
【24h】

Portal vein and systemic adiponectin concentrations are closely linked with hepatic glucose and lipoprotein kinetics in extremely obese subjects

机译:在极度肥胖的受试者中,门静脉和全身脂联素的浓度与肝糖和脂蛋白动力学密切相关

获取原文
获取原文并翻译 | 示例
           

摘要

Low systemic plasma adiponectin concentrations are associated with abnormalities in hepatic glucose and lipoprotein metabolism in obese people. However, the relationship between the delivery of adiponectin to the liver via the portal vein and hepatic glucose and lipoprotein metabolism is not known. We examined the relationship between hepatic substrate metabolism (glucose rate of appearance into plasma and hepatic very low-density lipoprotein [VLDL]-triglyceride [TG] and VLDL-apolipoprotein B-100 [apoB-100] secretion rates, determined by using stable isotope-labeled tracer techniques) and portal vein adiponectin concentration, in 8 insulin-resistant, extremely obese subjects (body mass index, 65 ± 7 kg/m 2). Portal vein adiponectin concentration was inversely associated with basal glucose rate of appearance (r = -0.820, P =.013) and VLDL-TG (r = -0.823, P =.012) and VLDL-apoB-100 (r = -0.787, P =.020) secretion rates. Very similar correlations were obtained for radial artery adiponectin as a result of a mirroring relationship between portal and arterial adiponectin concentrations (r = 0.899, P =.002) and the absence of significant arteriovenous concentration differences (P =.570). Insulin resistance, assessed with the homeostasis model assessment score, was also strongly associated with hepatic glucose and lipid metabolic parameters, as well as with adiponectin concentrations in the portal vein and radial artery. These results suggest that adiponectin delivery to the liver, whether via the portal or the systemic circulation, may be an important regulator of basal hepatic glucose, VLDL-TG, and VLDL-apoB-100 production rates in obese people, possibly through direct effects on the liver or changes in hepatic insulin sensitivity. However, portal vein adiponectin does not appear to be superior to arterial adiponectin as a marker of hepatic metabolic dysregulation. Additional studies are needed to elucidate the mechanism(s) responsible for the strong association we observed between adiponectin and hepatic substrate metabolism.
机译:系统性血浆脂联素浓度过低与肥胖人群的肝葡萄糖和脂蛋白代谢异常有关。然而,脂联素经门静脉输送至肝脏与肝葡萄糖和脂蛋白代谢之间的关系尚不清楚。我们检查了肝底物代谢(血浆中葡萄糖的出现率与肝极低密度脂蛋白[VLDL]-甘油三酸酯[TG]和VLDL-载脂蛋白B-100 [apoB-100]分泌率之间的关系,该值是通过使用稳定同位素确定的)示踪技术)和门静脉脂联素浓度在8位胰岛素抵抗,极度肥胖的受试者中(体重指数65±7 kg / m 2)。门静脉脂联素浓度与基础葡萄糖出现率呈负相关(r = -0.820,P = .013)和VLDL-TG(r = -0.823,P = .012)和VLDL-apoB-100(r = -0.787) ,P = .020)分泌率。由于门脉和动脉脂联素浓度之间存在镜像关系(r = 0.899,P = .002)并且没有明显的动静脉浓度差异(P = .570),因此radial动脉脂联素获得了非常相似的相关性。用稳态模型评估评分评估的胰岛素抵抗也与肝葡萄糖和脂质代谢参数以及门静脉和radial动脉中脂联素浓度密切相关。这些结果表明,脂联素通过门静脉或全身循环输送到肝脏可能是肥胖人群基础肝葡萄糖,VLDL-TG和VLDL-apoB-100生产率的重要调节剂,可能是通过直接影响肝脏或肝胰岛素敏感性的变化。然而,门静脉脂联素作为肝代谢失调的标志物似乎并不优于动脉脂联素。需要进一步的研究来阐明导致我们观察到的脂联素与肝底物代谢之间的强关联的机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号